Gilead Sciences, Inc. (GILD) Shares Bought by Hodges Capital Management Inc.
Hodges Capital Management Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,746 shares of the biopharmaceutical company’s stock after buying an additional 9,704 shares during the period. Hodges Capital Management Inc.’s holdings in Gilead Sciences were worth $2,459,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. Chicago Partners Investment Group LLC boosted its position in Gilead Sciences by 131.8% in the second quarter. Chicago Partners Investment Group LLC now owns 3,312 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 1,883 shares in the last quarter. IFP Advisors Inc boosted its position in Gilead Sciences by 18.1% in the second quarter. IFP Advisors Inc now owns 33,487 shares of the biopharmaceutical company’s stock valued at $2,370,000 after buying an additional 5,144 shares in the last quarter. JLB & Associates Inc. acquired a new stake in Gilead Sciences in the second quarter valued at approximately $8,068,000. Callahan Advisors LLC boosted its position in Gilead Sciences by 4.7% in the second quarter. Callahan Advisors LLC now owns 82,759 shares of the biopharmaceutical company’s stock valued at $5,858,000 after buying an additional 3,731 shares in the last quarter. Finally, Rand Wealth LLC boosted its position in Gilead Sciences by 0.7% in the second quarter. Rand Wealth LLC now owns 20,418 shares of the biopharmaceutical company’s stock valued at $1,445,000 after buying an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 73.99% of the company’s stock.
A number of analysts have weighed in on GILD shares. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Monday, July 17th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research report on Wednesday, June 21st. Finally, Deutsche Bank AG started coverage on shares of Gilead Sciences in a research report on Friday, June 23rd. They issued a “buy” rating and a $79.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $85.66.
Gilead Sciences, Inc. (GILD) opened at 82.14 on Friday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The stock has a market capitalization of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14. The company’s 50-day moving average is $80.97 and its 200 day moving average is $71.66.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period last year, the business earned $3.08 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 over the last three months. 1.30% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.